Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 06:10PM GMT
Release Date Price: €66.8 (+1.15%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. I'm Salveen Richter, a biotechnology analyst at Goldman Sachs. I'm pleased to have with us Arrowhead Therapeutics with Chris Anzalone, CEO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Chris, thanks for joining us. And maybe a question here on your overall portfolio. You've got First data emerging and extrahepatic tissues.

can you just help us understand as you look to go outside the liver, why you chose lung and solid tumors as your first target and where you're going on the Ford there?

Christopher R. Anzalone
Arrowhead Pharmaceuticals, Inc. - CEO, President & Director

Sure. Thanks very much. And thanks for having us. It's really a pleasure to be here, and good afternoon. So look lung wasn't, for us, was a bit of a no-brainer. It's a target-rich environment. There is a number of well-validated targets to go after a number of disease

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot